There are 11 resources available
Toxicity issues with Immune Check Points inhibitors
Presenter: John Haanen
Session: Session 7
Use of checkpoint inhibitors in patients with AID and chronic viral infections
Presenter: Aurélien Marabelle
Session: Session 7
Brain metastasis as a target
Presenter: Aurélien Marabelle
Session: Session 6: Efficacy evaluation of Immune Check Points Inhibitors: Recist 1.1, iRecist or Ir Recist? The issue and risk of hyper-progression
The point of view of the Immunologist
Presenter: John Haanen
Session: Session 5: Refining patient selection: Immuno-score, -profiling, -gram and Tumor Mutation Burden
What is the rational for adding anti-angiogenics to Immune Check-Point Inhibitors?
Presenter: Solange Peters
Session: Session 4
In TPS>50%, what is best in 1st-line: single agent Pembrolizumab or CT-IO combination?
Presenter: Solange Peters
Session: Session 3
Debate Pro: one size fits all!
Presenter: Maurice Pérol
Session: Session 2: Are all fit patients candidates for 1st-line treatment with Immune Check Point Inhibitors?
Debate Contra: Patients should be selected based on predictive biomarkers
Presenter: David Planchard
Session: Session 2: Are all fit patients candidates for 1st-line treatment with Immune Check Point Inhibitors?
State-of-the-art: Immunotherapy with Immune Check Point Inhibitors of Locally Advanced and Metastatic Non-Small Cell Lung Cancer in 1st and later lines
Presenter: Maurice Pérol
Session: Session 1
Welcome and introduction
Presenter: John Haanen
Session: Welcome and introduction